Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-10-19
Based on 658 first isolates · URO · Cystitis (lower UTI) · 2024-10-20 → 2025-10-19
Urology
Per-organism detail: URO urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 86 % (83 %–88 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (5 %), Klebsiella pneumoniae (4 %), Pseudomonas aeruginosa (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
86 %
88 %
n = 59
meropenem MEM
trend · Escherichia coli reserve
83 %
81 %
n = 59
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
79 %
81 %
n = 59
mecillinam MEC
trend · Escherichia coli lower UTI only
77 %
76 %
n = 59
ciprofloxacin CIP
trend · Escherichia coli
73 %
83 %
n = 59
ceftriaxone CRO
trend · Escherichia coli
72 %
80 %
n = 59
66 %
76 %
n = 59
trimethoprim TMP
trend · Escherichia coli lower UTI only
65 %
68 %
n = 59
45 %
47 %
n = 59
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
14 %
15 %
n = 59
4 %
3 %
n = 59
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
8 %
n = 59

Most likely organisms for this profile

Escherichia coli
58 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
5 %
Pseudomonas aeruginosa
4 %
Staphylococcus aureus
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.